We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.
Expanding into the U.S. ingredient market can feel overwhelming, with strict FDA rules to follow. That’s why we offer support with GRAS notices, self‑affirmed GRAS reviews, and NDI notifications. From identifying the right pathway to preparing submissions, we’re here to ease the process and help you move forward with your ingredient launch.
The GRAS pathway reviews safety data, prepares a dossier, and includes an expert panel before FDA submission. NDIN applies to dietary ingredients not marketed before October 15, 1994 and requires a notification with identity, use, and safety data. Here’s how both processes typically flow:
We focus on three core ingredient compliance services that are essential when entering the U.S. market. These pathways form the foundation for proving safety, meeting FDA expectations, and moving your ingredient forward with clarity and support:
Preparation and submission of GRAS notices to the FDA, ensuring your ingredient meets safety standards for food use.
Coordination of expert panel reviews and evidence packages so safety can be established without formal FDA review.
Guidance through the FDA’s NDI notification process for dietary ingredients introduced after October 15, 1994.
Some ingredients need additional groundwork before they’re submission-ready. These supporting services can strengthen your dossier and improve your chances of a smooth FDA acceptance.
We help organize safety studies through our trusted CRO network, following OECD and FDA standards.
Our team supports the drafting and publishing of scientific data to strengthen your submission.
We calculate expected intake using ADI and EDI models to support your safety justification.
We write a new dossier or review your draft dossier to ensure regulatory completeness and consistency before submission.
FDA facility registration and serve as your U.S. Agent to ensure continuous regulatory compliance and seamless communication with FDA.
We ensure FDA compliance by overseeing supplier verification and managing all import-related regulatory responsibilities.
Some of the world’s leading ingredient manufacturers and biotech companies work with Quality Smart Solutions to navigate FDA GRAS and NDI compliance. Join the companies already bringing their ingredients to the U.S. market with confidence.
Yes, you can submit a GRAS Notice after self-affirming. This is common when retailers, partners, or international buyers require formal FDA acknowledgment. It’s also a smart move if the regulatory landscape shifts and self-affirmed GRAS faces additional scrutiny.
Not always. If sufficient publicly available safety data exists — peer-reviewed studies, historical use data, or established safety profiles — clinical studies may not be required. A gap assessment is the best way to determine what evidence you already have and what, if anything, is missing before moving forward.
Panel members must have relevant qualifications in fields such as toxicology, pharmacology, food science, or nutrition. Critically, they must be independent from the company seeking GRAS status, meaning no financial or professional conflicts of interest. We help identify and coordinate qualified panelists as part of our process.
Yes. If your ingredient is intended for use in both conventional food and dietary supplements, each application may require a separate regulatory pathway. GRAS covers food use, while an NDI Notification is required for dietary supplement use if the ingredient was not marketed before October 15, 1994. Our team can assess both requirements and help you plan accordingly.
Yes, if the ingredient meets the definition of a new dietary ingredient and is used in dietary supplements sold in the U.S., an NDI Notification is required regardless of where it is manufactured. The obligation is tied to the U.S. market, not the country of origin.
FDA doesn’t technically “reject” GRAS Notices — instead, they may issue a “no questions” letter, cease to evaluate, or respond with questions requiring clarification. If FDA raises concerns or ceases evaluation, we help identify the gaps, address the feedback, strengthen your evidence package, and determine the best path forward, whether that means resubmission or an alternative pathway.
No. GRAS is a U.S.-specific regulatory designation and is not automatically recognized in other markets. However, a well-documented GRAS dossier can serve as a strong foundation for safety submissions in other jurisdictions, such as Novel Food applications in the EU or UK, and may help expedite reviews in some cases. Our team supports multi-market regulatory strategies if you’re planning a broader launch.
Stay informed on the latest developments in GRAS and ingredient compliance. Explore blogs, webinars, and news curated specifically for this category.
Not sure whether GRAS or NDI is the right pathway for your ingredient? Book a free strategy call with our team and we’ll help you find the best route to FDA compliance.